Clinical Trials Browser

Phase 1/2 × Advanced HCC × tislelizumab × Clear all

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced HCC